<unk> , sold under the brand name Suboxone among others, is a fixed-dose combination medication that includes<unk>  and naloxone. It is used to treat opioid use disorder, and reduces the mortality of opioid use disorder by 50% (namely by reducing the risk of overdose on full-agonist opioids such as heroin or fentanyl). It relieves cravings to use and withdrawal symptoms.<unk>  is available for use in two different forms, under the tongue or in the cheek. Side effects may include respiratory depression (decreased breathing), small pupils, sleepiness, and low blood pressure. The risk of overdose with<unk>  (unless combined with other sedating substances) is exceedingly low, and lower than with methadone. However, people are more likely to stop treatment on<unk>  than methadone.<unk>  (like methadone) is a treatment option during pregnancy.<unk> , at lower doses, results in the usual opioid effects; however, high doses beyond a certain level do not result in greater effects. This is believed to result in a lower risk of overdose than some other opioids. Naloxone is an opioid antagonist that competes with and blocks the effect of other opioids (including<unk>  if given by injection. Naloxone is poorly absorbed when taken by mouth and it is added to decrease the risk that people will misuse the medication by injection. Misuse by injection or use in the nose, however, still occurs. Rates of misuse in the United States appear to be lower than with other opioids. The combination formulation was approved for medical use in the United States in October 2002, and in the European Union in November 2017. A generic version was approved in the US in June 2018. In 2017, it was the 288th most commonly prescribed medication in the United States, with more than one million prescriptions.
Buprenorphine/naloxone
Oxycodone/naloxone
Buprenorphine/naltrexone
Fentanyl/fluanisone
Buprenorphine/samidorphan
Dextromethorphan/quinidine
Naloxone
Nalorphine dinicotinate